HelpHelp About Us Contact Contact Us Help Help
Press Release Service
user name password
Client login:   
First time user sign up Forgot your login info?
Website Directory     Submit Website

Search
EmailWire News Links

Home > News By Company > LegalView

Print e mail rss del Y! myWeb Tweet
 

LegalView Recounts the Results of a Recent Mesothelioma Study That Reported High Survival Rates Among Patients Taking New Treatment

LegalView reported the results of an Italian study to its mesothelioma blog readers; the results detailed a positive outcome and increased survival rate for elderly pleural mesothelioma victims. The study, recently published in a British medical journal,

(EMAILWIRE.COM, August 15, 2008 ) Denver, CO - LegalView, the most comprehensive legal resource available on the Web, recounted the results of an Italian study to its mesothelioma information (http://mesothelioma.legalview.com/blog) blog readers. The study attempted to increase the survival rate of elderly pleural mesothelioma patients (http://mesothelioma.legalview.com/mesothelioma-treatment.aspx) by combining two medications: Alimta (pemtrexed) and Paraplatin (carboplatin). The results of the study were released in a June issue of the British Journal of Cancer and the conclusions detailed the highly-effective treatments, which increased the survival rate among pleural mesothelioma patients 65 years of age or older.

Mesothelioma is an incurable cancer that is often attributed to the inhalation of asbestos fibers and dust containing tremolite. Asbestos is a known carcinogen, according to the Environmental Protection Agency (EPA), which is responsible for regulating the cleanup of the hazardous material. Asbestos was often prized for its ability to remain fire-resistant, while being produced cheaply, and served as a key ingredient in many products including insulation that was implemented into homes, apartment complexes, universities, schools, business offices and hospitals around the country. Individuals who suffer from mesothelioma cancer are advised to speak with a knowledgeable mesothelioma attorney (http://mesothelioma.legalview.com/find-mesothelioma-lawer.aspx) in order to better educate themselves on the possibility for developing a mesothelioma lawsuit (http://mesothelioma.legalview.com/mesothelioma-lawsuit-results.aspx). Due to the extremely costly medical bills associated with increasing survival rate among mesothelioma cancer victims, developing litigation may result in monetary compensation to assist with those medical bills.

LegalView not only offers resources on the most recent mesothelioma news and clinical trials, but also offers information on a variety of other legal issues afflicting millions of Americans. Most recently, LegalView updated several of its pharmaceutical drug information portals with news on updates and recalls; some of the portals include Viapro, Ketek and the Zimmer Durom cup.

The development of the Viapro information portal occurred after the U.S. Food and Drug Administration (FDA) issued a press release on the recall of the drug because of contamination of a harmful chemical known as thiomethisosildenafil. The male sexual-enhancement prescription drug, manufactured by EG Labs, is used to treat erectile dysfunction (ED). The undeclared ingredient may be harmful to patients especially when interacting with nitrates found in other prescription drugs. The Viapro recall (http://viapro.legalview.com) occurred because the drug may cause dangerously low levels of blood pressure among patients also taking nitroglycerin for diabetes, high blood pressure, high cholesterol or heart disease.

Ketek, which is an antibiotic used to treat upper respiratory infections such as pneumonia, bronchitis and sinusitis, had its warning labels increased recently due to the threat of liver disease among patients consuming the drug. To learn more about the Ketek side effects (http://ketek.legalview.com), visit http://ketek.legalview.com/.

Also among the recently updated information portals is that of the Zimmer Durom cup. Zimmer Holdings has ceased production of its Durom cup because of complaints that the hip socket was failing among many patients. Although the company has ceased production of the hip socket, pending internal investigations into the potential failure, the hip socket has already been used in over 12,000 hip replacement procedures since its introduction to the market in 2006. Patients who may be at risk for the Durom cup failure (http://zimmer-durom-cup.legalview.com) should seek medical attention immediately to ensure no further damage occurs.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.


Contact Information:
LegalView
Katie Kelley
Tel: 720-771-3246
Email us


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Press Release Keywords:

mesothelioma, cancer, lung cancer, lawsuit, lawyer, attorney, legal consultation, asbestos exposure, asbestos dust, asbestos fibers, mesothelioma law firm, mesothelioma lawsuit

Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International

Equityallianceir.com





Penny Stocks to Watch

Sign up for hot penny stock picks
Gains of 500%+ possible!

Premiumstockpicks.com/landing/




Your text Ads & 

PR

Text Ads plus unlimited press releases, One release featured/Day for only $575 per month.

Read more on Text Ads & PR






Your text Ads Here!

Text Ads are only $289 per month. Ads are placed same day.

More on Text Ads Advertising




 

Search


Advertising | How to contact us | Privacy Statement | EmailWire Press Releases | Partnership Opportunities

EmailWire is a press release distribution service of GroupWeb Media LLC.

© Copyright GroupWeb Media LLC 2012